BioMarin's $4.8B Amicus Buyout: Growth & Value
Update: 2025-12-22
Description
BioMarins acquisition of Amicus Therapeutics for $4.8 billion adds two lysosomal storage disorder drugs, Galafold and Pombiliti-Opfolda, to its portfolio, boosting sales potential and reducing reliance on top seller Voxzogo. The deal is expected to increase non-GAAP diluted earnings per share in the first year and has Wall Street bullish, with a consensus moderate buy rating and targets up to $122, suggesting potential 100% upside by the end of 2026.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
